Compare CYTK & HII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYTK | HII |
|---|---|---|
| Founded | 1997 | 1886 |
| Country | United States | United States |
| Employees | N/A | 44000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 11.5B |
| IPO Year | 2004 | 2010 |
| Metric | CYTK | HII |
|---|---|---|
| Price | $76.84 | $327.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 6 |
| Target Price | $89.26 | ★ $411.33 |
| AVG Volume (30 Days) | ★ 1.7M | 538.5K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 1.52% |
| EPS Growth | N/A | ★ 10.24 |
| EPS | N/A | ★ 9.06 |
| Revenue | $13,368,000.00 | ★ $12,484,000,000.00 |
| Revenue This Year | $7.37 | $4.82 |
| Revenue Next Year | $310.19 | $6.28 |
| P/E Ratio | ★ N/A | $36.51 |
| Revenue Growth | N/A | ★ 8.23 |
| 52 Week Low | $34.60 | $262.66 |
| 52 Week High | $88.31 | $460.00 |
| Indicator | CYTK | HII |
|---|---|---|
| Relative Strength Index (RSI) | 45.54 | 66.90 |
| Support Level | $73.95 | $295.64 |
| Resistance Level | $79.66 | $333.07 |
| Average True Range (ATR) | 2.91 | 12.11 |
| MACD | -0.37 | 3.96 |
| Stochastic Oscillator | 33.77 | 93.59 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Huntington Ingalls Industries is the largest independent military shipbuilder in the US, spun out from Northrop Grumman in 2011. It operates three segments, two of which are storied shipyards: Ingalls produces non-nuclear-powered ships, including amphibious landing ships and Arleigh Burke-class destroyers, while Newport News produces nuclear-powered ships as the only producer of Gerald Ford-class aircraft carriers and a major subcontractor on Virginia- and Columbia-class nuclear submarines. HII shares production of destroyers and nuclear submarines with General Dynamics' Bath Iron Works and Electric Boat shipyards, respectively. The company's mission technologies segment produces uncrewed sea vessels and provides a range of IT and other services to US government agencies.